Acute aortic dissection
- PMID: 36640801
- DOI: 10.1016/S0140-6736(22)01970-5
Acute aortic dissection
Abstract
Although substantial progress has been made in the prevention, diagnosis, and treatment of acute aortic dissection, it remains a complex cardiovascular event, with a high immediate mortality and substantial morbidity in individuals surviving the acute period. The past decade has allowed a leap forward in understanding the pathophysiology of this disease; the existing classifications have been challenged, and the scientific community moves towards a nomenclature that is likely to unify the current definitions according to morphology and function. The most important pathophysiological pathway, namely the location and extension of the initial intimal tear, which causes a disruption of the media layer of the aortic wall, together with the size of the affected aortic segments, determines whether the patient should undergo emergency surgery, an endovascular intervention, or receive optimal medical treatment. The scientific evidence for the management and follow-up of acute aortic dissection continues to evolve. This Seminar provides a clinically relevant overview of potential prevention, diagnosis, and management of acute aortic dissection, which is the most severe acute aortic syndrome.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests TC, TMS, and YvK declare no competing interests. MC is a consultant for Terumo Aortic, Medtronic, NEOS, and Endospan, received speaking honoraria from Cryolife Jotec and Bentley, and is a shareholder and co-founder of TEVAR and Ascense Medical. TEVAR and Ascense Medical are academy-based start-ups founded by qualified experts in the field of cardiothoracic and vascular surgery, and are research-oriented spinoffs with an interest in animal experimentation to improve current technologies for the treatment of cardiac and aortic diseases. At this stage, both entities are far away from being relevant companies or competitors since they neither have commercial products nor pre-released products on the market. The main actual interest is directed at the level of conceptual designs to improve the compliance of vascular substitutes or to facilitate device delivery. To allow full scientific liberty in the experimental research, MC has no function on the board of these companies (strategical level), nor does he fulfil any position at the operational level. MC also serves in a leading role in the committees for aortic guidelines of national and international societies (ie, European Association of Cardio-thoracic Surgery, and German Society for Thoracic and Cardiovascular Surgery) that both considered this founding membership role and shareholding as uncritical.
Comment in
-
AATD as a genetic risk factor for aneurysmal disease.Lancet. 2023 Nov 4;402(10413):1625-1626. doi: 10.1016/S0140-6736(23)01747-6. Lancet. 2023. PMID: 37925196 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
